TPH vs. PBYI

Last updated Jun 4, 2026

TPH (Tri Pointe Homes, Inc.) and PBYI (Puma Biotechnology, Inc.) are both stocks. TPH operates in Residential Construction (Consumer Cyclical), while PBYI operates in Biotechnology (Healthcare). Over the past 10 years, TPH returned 15.92%/yr vs -15.39%/yr for PBYI. At a 0.21 correlation, their price movements are largely independent.

Performance

TPH vs. PBYI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tri Pointe Homes, Inc. (TPH) and Puma Biotechnology, Inc. (PBYI). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TPH achieves a 49.19% return, which is significantly higher than PBYI's 14.45% return. Over the past 10 years, TPH has outperformed PBYI with an annualized return of 15.92%, while PBYI has yielded a comparatively lower -15.39% annualized return.

TPH

• 1D: -0.04%
• 1M: 0.30%
• YTD: 49.19%
• 6M: 36.56%
• 1Y: 57.34%
• 3Y*: 16.33%
• 5Y*: 13.64%
• 10Y*: 15.92%

PBYI

• 1D: -2.44%
• 1M: -9.56%
• YTD: 14.45%
• 6M: 31.21%
• 1Y: 105.43%
• 3Y*: 24.25%
• 5Y*: -9.60%
• 10Y*: -15.39%

*Multi-year figures are annualized to reflect compound growth (CAGR)

TPH vs. PBYI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
TPH Tri Pointe Homes, Inc.	49.19%	-13.21%	2.43%	90.42%	-33.35%	61.68%	10.72%	42.54%	-39.01%	56.10%
PBYI Puma Biotechnology, Inc.	14.45%	95.08%	-29.56%	2.36%	39.14%	-70.37%	17.26%	-57.00%	-79.41%	221.99%

Correlation

The correlation between TPH and PBYI is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.13
Correlation (3Y) Calculated over the trailing 3-year period	0.22
Correlation (5Y) Calculated over the trailing 5-year period	0.20
Correlation (10Y) Calculated over the trailing 10-year period	0.21
Correlation (All Time) Calculated using the full available price history since Feb 1, 2013	0.21

Fundamentals

Market Cap TPH : $4.00B PBYI : $346.26M
EPS TPH : $2.08 PBYI : $0.48
PE Ratio TPH : 22.59 PBYI : 14.25
PS Ratio TPH : 1.27 PBYI : 1.52
PB Ratio TPH : 1.21 PBYI : 2.70
Total Revenue (TTM) TPH : $3.24B PBYI : $227.21M
Gross Profit (TTM) TPH : $1.07B PBYI : $169.14M
EBITDA (TTM) TPH : $274.34M PBYI : $46.97M

Return for Risk

TPH vs. PBYI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TPH

TPH Risk / Return Rank: 79
TPH Sharpe Ratio Rank: 74
TPH Sortino Ratio Rank: 80
TPH Omega Ratio Rank: 82
TPH Calmar Ratio Rank: 80
TPH Martin Ratio Rank: 77

PBYI

PBYI Risk / Return Rank: 83
PBYI Sharpe Ratio Rank: 82
PBYI Sortino Ratio Rank: 78
PBYI Omega Ratio Rank: 84
PBYI Calmar Ratio Rank: 88
PBYI Martin Ratio Rank: 86

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TPH vs. PBYI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Tri Pointe Homes, Inc. (TPH) and Puma Biotechnology, Inc. (PBYI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TPH	PBYI	Difference
Sharpe ratio Return per unit of total volatility	1.13	1.52	-0.39
Sortino ratio Return per unit of downside risk	2.35	2.18	+0.17
Omega ratio Gain probability vs. loss probability	1.32	1.35	-0.02
Calmar ratio Return relative to maximum drawdown	2.62	4.11	-1.50
Martin ratio Return relative to average drawdown	5.80	9.31	-3.51
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TPH vs. PBYI - Sharpe Ratio Comparison

The current TPH Sharpe Ratio is 1.13, which is comparable to the PBYI Sharpe Ratio of 1.52. The chart below compares the historical Sharpe Ratios of TPH and PBYI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	TPH	PBYI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.13	1.52	-0.39
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.37	-0.13	+0.50
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.38	-0.19	+0.57
Sharpe Ratio (All Time) Calculated using the full available price history	0.18	-0.04	+0.22

Drawdowns

TPH vs. PBYI - Drawdown Comparison

The maximum TPH drawdown since its inception was -70.06%, smaller than the maximum PBYI drawdown of -99.40%. Use the drawdown chart below to compare losses from any high point for TPH and PBYI.

Drawdown Indicators

	TPH	PBYI	Difference
Max Drawdown Largest peak-to-trough decline	-70.06%	-99.40%	+29.34%
Max Drawdown (1Y) Largest decline over 1 year	-17.47%	-25.78%	+8.31%
Max Drawdown (3Y) Largest decline over 3 years	-37.97%	-69.59%	+31.62%
Max Drawdown (5Y) Largest decline over 5 years	-47.00%	-85.86%	+38.86%
Max Drawdown (10Y) Largest decline over 10 years	-68.38%	-98.76%	+30.38%
Current Drawdown Current decline from peak	-0.04%	-97.52%	+97.48%
Average Drawdown Average peak-to-trough decline	-23.88%	-74.42%	+50.54%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.93%	11.36%	-3.43%

Volatility

TPH vs. PBYI - Volatility Comparison

The current volatility for Tri Pointe Homes, Inc. (TPH) is 0.48%, while Puma Biotechnology, Inc. (PBYI) has a volatility of 9.68%. This indicates that TPH experiences smaller price fluctuations and is considered to be less risky than PBYI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TPH	PBYI	Difference
Volatility (1M) Calculated over the trailing 1-month period	0.48%	9.68%	-9.20%
Volatility (6M) Calculated over the trailing 6-month period	29.53%	41.71%	-12.18%
Volatility (1Y) Calculated over the trailing 1-year period	40.54%	69.92%	-29.38%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	37.27%	75.83%	-38.56%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	41.98%	80.65%	-38.67%

Dividends

TPH vs. PBYI - Dividend Comparison

Neither TPH nor PBYI has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

TPH vs. PBYI - Profitability Comparison

The chart below illustrates the profitability comparison between Tri Pointe Homes, Inc. and Puma Biotechnology, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

TPH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Tri Pointe Homes, Inc. reported a gross profit of 502.02M and revenue of 507.90M. Therefore, the gross margin over that period was 98.8%.

PBYI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Puma Biotechnology, Inc. reported a gross profit of 34.40M and revenue of 44.80M. Therefore, the gross margin over that period was 76.8%.

TPH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Tri Pointe Homes, Inc. reported an operating income of 4.19M and revenue of 507.90M, resulting in an operating margin of 0.8%.

PBYI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Puma Biotechnology, Inc. reported an operating income of -3.83M and revenue of 44.80M, resulting in an operating margin of -8.5%.

TPH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Tri Pointe Homes, Inc. reported a net income of 5.54M and revenue of 507.90M, resulting in a net margin of 1.1%.

PBYI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Puma Biotechnology, Inc. reported a net income of -3.80M and revenue of 44.80M, resulting in a net margin of -8.5%.

Frequently Asked Questions

Can I hold both TPH and PBYI in my portfolio?

TPH and PBYI have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, TPH or PBYI?

PBYI has higher volatility (9.68%) compared to TPH (0.48%). In terms of maximum drawdown, TPH dropped -70.06% vs PBYI's -99.40%.

Which has better risk-adjusted returns?

PBYI currently has the higher Sharpe Ratio (1.52 vs 1.13), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.